Clinical Trial Update: TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy [Phase 1]

View source ↗

Summary

Phase 1 trial of TNFα and IL-2 coding oncolytic adenovirus TILT-123 as monotherapy for solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• TILT-123 (tilt-123)

Snippet

Sponsor: TILT Biotherapeutics Ltd. | Conditions: Solid Tumor | Phase 1 | Status: COMPLETED